NCT06300086Completed
Nationwide Utilization of Danish Government Electronic Letter System for Increasing Guideline-directed Medical Therapy in Chronic Kidney Disease
Source: ClinicalTrials.gov · Last updated 29 Sept 2025
Brief summary (registry, in English)
Kidney Disease Improving Global Outcomes (KDIGO) has recently updated the Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD). This update follows large placebo-controlled randomized trials, which established sodium-glucose cotransporter 2 inhibitors (SGLT2i) as an additional treatment option to reduce the risk of progression to kidney failure and cardiovascular disease in patients with CKD, both with and without diabetes or albuminuria. As a result, SGLT2i is now recommended to a broad range of CKD patients by KDIGO, along with established medical therapies such as renin-angiotensin system inhibition (RASi). Despite the significant adverse consequences of CKD and substantial evidence supporting guideline-directed medical therapy (GDMT) to improve patient outcomes, awareness of CKD among patients and providers remains disproportionately low. Innovative solutions are needed to increase awareness of CKD. Such a solution could potentially be the use of electronic nudge letters delivered to patients with CKD and their general practitioners (GPs) that highlight the importance of GDMT and inform them of updated guidelines. This study will investigate whether digital nudge letters delivered via the official Danish electronic letter system directly to patients with CKD and their associated GPs will improve GDMT in patients with CKD when compared to no letters.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 28388 (actual)
- First submitted
- 16 Feb 2024
- Start date
- 19 Aug 2024
- Primary completion date
- 19 Feb 2025
- Lead sponsor
- Tor Biering-Sørensen
- Diseases
- Chronic kidney disease
- NCT number
- NCT06300086
What you commit to
- Study type: Interventional
- Participants enrolled: 28388
- From 19 Aug 2024 to the primary completion date, 19 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- For patient-level intervention comparisons:
- 1\) Exemption from the official, mandatory Danish electronic mailbox system.
- For general practice-level intervention comparisons:
- Individuals on a patient list of general practice clinics run by Danish administrative Regions.
- Individuals not on a patient list of a general practice.
Who the study is looking for
- Age +18 years
- Diagnosis of CKD defined as at least one hospital encounter with the following ICD-10 codes in the primary diagnostic positions within ≤ 5 years: N18- N19, I12, E102, E112, E132, E142.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte Coordinator of this site? Confirm its status | Hellerup | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.